Nervous Disorder TRIZ Cases

Engineered promoters drive frataxin expression via AAV vectors, addressing Friedreich's ataxia treatment gaps.

Replacing sodium ions with other metal ions in oxybate reduces excessive daytime sleepiness while lowering total sodium intake.

Segmenting targeting and cytotoxic functions into VAR2CSA conjugates reduces toxicity to non-cancerous tissues while maintaining cancer cell killing efficiency.

Novel peptidic GLP-2 agonists utilize specific amino acid substitutions to extend biological activity duration.

Fat-soluble vitamins inhibit metabolic degradation of cannabidiol, increasing bioavailability while reducing side effects.

Segmented amyloid beta peptides with cysteine linkages induce robust antibody responses while avoiding adverse side effects from full-length antigens.

Cannabinoid anions prevent molecular aggregation via electrostatic repulsion, increasing bioavailability and reducing adverse events.

R-2-hydroxyglutarate suppresses FTO activity to resolve inconsistent treatment responses in IDH-mutant cancers.

Analyzing CYP24 SNPs and aberrantly spliced mRNA enables optimized calcitriol dosing that reduces hypercalcemic toxicity risks.

Disulphide-constrained peptides bind eIF4E directly, bypassing upstream resistance mechanisms that limit current cancer therapies.

Poria cocos peel extract addresses amyloid-beta plaques and tau tangles by inhibiting their formation while promoting nerve cell regeneration.

Transfected neural stem cells restore acetylcholine levels and cognitive function, addressing the limitation of palliative enzyme inhibition therapies.

HW-C-9 γ-AApeptides disrupt tau, synuclein, and amyloid-beta aggregation to treat neurodegenerative diseases.

NX218 restores glutamatergic neurotransmission by potentiating excitatory currents, addressing impaired synaptic transmission in neurological disorders.

Segmented antibody panels resolve detection specificity issues by distinguishing pathological tau species in cerebrospinal fluid.

AAV-mediated HIF1-alpha expression boosts neurotrophic factors, extending survival in ALS models.

Pulsed blood plasma dosing regimens stimulate neurogenesis and improve cognitive function while reducing neuroinflammation beyond protein half-life limits.

Antibody sequence modifications resolve the trade-off between low production yield and insufficient thermal stability in Alzheimer's therapies.

Alginate encapsulation protects cannabinoids from degradation while permeation enhancers drive uptake across the blood-brain barrier.

SAP-Fc fusion proteins eliminate fatal amyloid deposits by inducing rapid phagocytosis through optimized Fc domain mutations.

Three-phase chromatography separates hydrophobic rhGALC from cell culture contaminants, achieving high purity and yield for enzyme replacement therapy.

Myricanol derivatives clear soluble tau intermediates to treat neurodegenerative diseases.

Nanobodies bind to the agonist-bound active state of mu-opioid receptors, stabilizing specific conformations for structural analysis.

Segmented insulin isoforms treat diabetes and Alzheimer's disease by inhibiting amyloidosis while maintaining glucose regulation.

siRNA-mediated ABCD1 mRNA suppression increases vector yield while intrathecal administration minimizes cardiac toxicity.

Segmenting polmacoxib and pregabalin into distinct immediate and sustained release layers prevents chemical interaction while maintaining stability.

Optimized nicotine and amphetamine dosages improve treatment efficacy while reducing sensory overload intensity and anxiety symptoms.

Acetal linkers attach polymers to proteins, shielding them from proteolytic degradation and reducing immunogenicity while maintaining therapeutic efficacy.

An AAV vector delivers cholesterol 24-hydroxylase to restore central nervous system lipid homeostasis.

Proteolytic removal of a propeptide directs PEG attachment to specific lysine residues, preserving receptor binding activity and blood-brain barrier transport.

Bauhinia extract upregulates neprilysin and induces autophagy, reducing neuron death without toxic side effects.

A benzene derivative compound protects and repairs damaged nerve tissue.

Gelling polymers and solvent-resistant films prevent extraction via injection or insufflation, reducing overdose risk from multi-tablet ingestion.

Whey protein isolate supplementation increases glutathione levels to address oxidative stress and improve adaptive behavior scores.

Dextran sulfate and chitosan nanoparticles deliver CNTF and OSM to restore visual function in degenerating retinas.

A taurine and malic acid supplement composition delivers ergogenic effects through a specific 2:1 molar ratio.

AAV-mediated AADC expression in substantia nigra restores levodopa conversion, resolving late-stage therapeutic unresponsiveness.

Amino acid substitutions in GLP-1R agonistic peptides lower receptor activity to minimize gastrointestinal adverse effects while maintaining metabolic benefits.

Film-coated risdiplam tablets eliminate reconstitution needs by using tartaric acid and crospovidone for stable, room-temperature storage.

Methanol extraction of Hornstedtia scyphifera yields an immunosuppressive substance that inhibits IL-2 release from activated T-cells.

Water-soluble DDQ and MitoQ molecules inhibit Aβ-Drp1 interaction, resolving insolubility bottlenecks in neurodegenerative treatments.

Segments immediate and controlled release components in sublingual tablets to resolve the trade-off between rapid onset and prolonged therapeutic duration.